Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 13/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.47 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407964 | 0.94 | APP (0.45) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3412507 | 0.93 | APP (0.44) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3411193 | 0.90 | BDKRB1 (0.58) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3413288 | 0.89 | PSEN1 (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4383315 | 0.89 | APP (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3406152 | 0.88 | PSEN1 (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3412098 | 0.88 | APP (0.47) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3407697 | 0.86 | BDKRB1 (0.47) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3407809 | 0.86 | BDKRB1 (0.46) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4113323 | 0.85 | PSEN1 (0.49) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | claimed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | claimed |
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | APP 2337/4885PSEN1 575/4885PSEN2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.